AstraZeneca Names Rick Suarez US President to Lead $50 Billion Investment Strategy
Key Insights
AstraZeneca has appointed Rick R. Suarez (search) as Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit to oversee the company's $50 billion US investment plan.
Suarez will lead execution of the investment strategy, including construction of a $4.5 billion manufacturing facility in Virginia, which represents AstraZeneca's largest single manufacturing investment globally.
The strategic investment supports AstraZeneca's ambitious goal of reaching $80 billion in total revenue by 2030, with half expected to come from the US market.
AstraZeneca has appointed Rick R. Suarez (search) as Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit, positioning him to lead the pharmaceutical giant's ambitious $50 billion US investment strategy. The appointment, effective immediately, places Suarez at the helm of executing one of the industry's most significant expansion plans as AstraZeneca targets $80 billion in total revenue by 2030.
Strategic Investment Leadership
Suarez will oversee the company's previously announced $50 billion investment in US research, development and manufacturing operations. Central to this expansion is the construction of a $4.5 billion manufacturing facility in Virginia, marking AstraZeneca's largest single manufacturing investment globally. The investment strategy underpins the company's goal of generating $80 billion in total revenue by 2030, with half expected to originate from the US, which represents AstraZeneca's largest market.
"We are operating at a moment of unprecedented scientific opportunity," Suarez stated. "Our responsibility is to translate that science into results for patients and for the US healthcare system. By strengthening our US manufacturing and R&D footprint, we will expand access to innovative medicines, create highly skilled jobs, and deliver long-term value."
Executive Background and Experience
Suarez brings more than 20 years of experience in the US healthcare sector, with leadership roles spanning commercial, medical and market access functions at AstraZeneca. He returns to the US after serving as Country President for Spain since 2020, where he led one of AstraZeneca's strongest performing European markets.
During his tenure in Spain, Suarez demonstrated significant strategic leadership by expanding the country's role in global clinical development and positioning Barcelona as a strategic hub for innovation. He established a new global hub in Barcelona and launched the AstraZeneca Healthcare Innovation Hub, committing more than €10 million to digital health and data-driven initiatives focused on translational innovation.
Organizational Responsibilities
In his new role, Suarez will have full responsibility for AstraZeneca's US BioPharmaceuticals organization, with accountability for performance, growth and execution across the entire portfolio. He will be based at AstraZeneca's US headquarters in Wilmington, Delaware.
Suarez's career with AstraZeneca began in 1999 as a pharmaceutical sales specialist, and he has since worked across multiple business functions including marketing, medical affairs and market access. Born in the United States and raised in New Haven, Connecticut, his appointment represents a homecoming as he takes on this critical leadership role.
Company Context
AstraZeneca operates as a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines across three key therapeutic areas: Oncology (search), Rare Diseases (search), and BioPharmaceuticals, including Cardiovascular (search), Renal & Metabolism (search), and Respiratory & Immunology (search). Based in Cambridge, UK, the company's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.